Connor Clark & Lunn Investment Management Ltd. Takes Position in DaVita Inc. (NYSE:DVA)

Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 12,459 shares of the company's stock, valued at approximately $2,042,000.

A number of other institutional investors have also recently bought and sold shares of DVA. Transcendent Capital Group LLC bought a new stake in DaVita in the 3rd quarter valued at about $25,000. Blue Trust Inc. boosted its holdings in DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company's stock valued at $29,000 after purchasing an additional 78 shares during the period. Family Firm Inc. bought a new stake in DaVita in the 2nd quarter valued at about $43,000. Versant Capital Management Inc lifted its holdings in shares of DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company's stock worth $45,000 after acquiring an additional 155 shares during the period. Finally, Friedenthal Financial bought a new stake in shares of DaVita during the 2nd quarter worth approximately $48,000. Institutional investors own 90.12% of the company's stock.

DaVita Price Performance

DVA stock traded up $0.99 during trading on Tuesday, reaching $167.98. 517,776 shares of the company were exchanged, compared to its average volume of 824,427. The company has a 50-day moving average of $158.34 and a two-hundred day moving average of $148.65. The company has a market capitalization of $13.77 billion, a price-to-earnings ratio of 18.12, a P/E/G ratio of 0.93 and a beta of 0.89. DaVita Inc. has a twelve month low of $98.26 and a twelve month high of $169.12. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. During the same quarter in the prior year, the company earned $2.85 earnings per share. DaVita's revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, equities analysts predict that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Insider Buying and Selling at DaVita

In other DaVita news, CEO Javier Rodriguez sold 9,881 shares of the company's stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $162.85, for a total value of $1,609,120.85. Following the completion of the transaction, the chief executive officer now directly owns 887,835 shares in the company, valued at approximately $144,583,929.75. This represents a 1.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 2.00% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on DVA shares. Bank of America upped their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an "underperform" rating in a report on Wednesday, August 7th. UBS Group upped their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. Finally, Truist Financial upped their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a research report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, DaVita has an average rating of "Hold" and a consensus price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.